All episodes

222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment

221: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing

220: The last-minute push for drug pricing reform, Alnylam's success, and Sarepta's gamble

219: Helen Branswell on monkeypox, plus: an FDA controversy and fake Alzheimer's data

218: Well-paid CEOs, behind the scenes at Moderna, & Biogen's CEO search

217: CRISPR for the heart, biotech's recovery, & what it means to be a 'hot girl'

216: VC malaise, FDA confusion, & yet another Alzheimer's debate

215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

214: Juul's doomsday, Merck's buyout plans, & the next Theranos verdict

213: How the Fed affects biotech, Paul Offit on vaccines for kids, & another Alzheimer's setback

212: Applause-worthy cancer data, the long wait for Novavax, & the next FDA controversy

211: Biotech's catch-22, a $100 genome, & dealing with monkeypox

210: Covid vaccines for the youngest kids, ASCO preview, & a biotech CEO’s arrest on murder charges

Episode 209: Mysterious infections, dwindling Covid funds, & Shkreli out of prison

Episode 208: A CEO's arrest, Pfizer's big deal, & Covid on the rise

Episode 207: Succession at Biogen, surprises at Vertex, & a potential superspreader dinner

Episode 206: How cancer-killing cell therapies work, biotech's endless downturn, & an FDA conundrum

Episode 205: An ominous biotech deal, vaccines for kids, & 'breakthrough' devices

Episode 204: Leana Wen on the pandemic's new normal and whether Twitter is real life

Episode 203: What's next for Roche, a debate over second boosters, & Vertex's recent success

Introducing: Color Code

Episode 202: Helen Branswell on the pandemic, plus the next FDA debate & the perks of being a CEO

Episode 201: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas

Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV

Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR

Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron

Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay

Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic

Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids

Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron

Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project

Episode 192: Michael Gilman on the future of RNA drugs, plus #JPM22 in review and more Biogen news

Episode 191: Craig Spencer on the Omicron surge + biotech in 2022, & the Elizabeth Holmes verdict

Episode 190: Covid in 2022, J.P. Morgan bows to pressure, & the year in review

Episode 189: Biogen, Biogen, Biogen, with a dash of Omicron

Episode 188: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron

Episode 187: Biogen’s scientific succession & Michael Osterholm on pandemic Thanksgiving

Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Episode 185: John Maraganore on his next act, plus Moderna's setback & the drug pricing reform saga

Episode 184: Vaccines for kids, inside Operation Warp Speed, & a big biotech resignation

Episode 183: Greg Zuckerman on the vaccine race, plus Biogen's troubled launch

Episode 182: The FDA star search, more booster debates, & the future of mRNA

Episode 181: Brent Hodge on filming Shkreli, the next NIH director, and a looming FDA deadline

Episode 180: Health equity 'tourism,' an $11B biopharma acquisition, & a bony Covid protest

Episode 179: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm's slow rollout

Episode 178: Futuristic prosthetics, a treatment for ALS, & intrigue at the Holmes trial

Episode 177: Bijan Salehizadeh on Covid tests, plus Verily's moment of truth

Episode 176: Elizabeth Holmes on trial, FDA in disarray, & the quest for Covid antivirals

Episode 175: Dorit Reiss on vaccine mandates, plus biotech's messy summer

Episode 174: Biotech's trust issues, overwhelmed health workers, & the nuances of insider trading

Episode 173: Biden's drug pricing plan, Wall Street's Alzheimer's fixation, & daily 5 a.m. alarms

Episode 172: The mRNA gold rush, Delta's alarming rise, & the next treatment for Alzheimer's

Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen

Episode 170: Céline Gounder on breakthrough infections, plus the power of lobbying

Episode 169: Dan Diamond on covering Biden, plus the FDA's future, & the latest Aduhelm twist

Episode 168: Aduhelm's latest twist, & how Covid variants are shaping the summer

Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,

Episode 166: FDA inner workings, GSK's foggy future, & the alarming rise in colorectal cancer

Episode 165: Paul Offit on the Covid vaccine booster debate, & Robyn Karnauskas' call of the decade

Episode 164: Every angle on the FDA's polarizing approval of Biogen's Alzheimer's drug

Episode 163: Marilynn Marchione on covering the CRISPR babies scandal

Episode 162: Scott Gottlieb on Covid and grilling, plus how Zolgensma has changed SMA

Episode 161: Biotech meme stocks, the lessons of Spanish Flu, & becoming a pandemic celebrity

Episode 160: Global Covid-19 failures, a sluggish CDC, and a boisterous STAT Health Tech Summit

Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging

Episode 158: Angela Rasmussen on Russia's vaccine controversy, plus Biden's drug pricing punt

Episode 157: Mercedes Carnethon on outdoor masking, FDA in limbo, & gene therapy's uncertain upside

Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19

Episode 155: AstraZeneca's vaccine woes, compassionate use, & giving out Covid vaccines

Episode 154: Eleanor Fox on Illumina’s FTC headache, plus Talkspace’s experiment

Episode 153: AstraZeneca and the very good, then quite bad, then deeply confusing week

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer

Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase

Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise

Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future

Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks

Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring

Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation

Episode 144: Remembering STAT's Sharon Begley

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy

Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021

Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution

Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021

Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered

Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary

Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old

Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5

Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's

Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials

Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos

Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting

Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest

Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round

Episode 128: AstraZeneca’s Covid-19 vaccine, coronavirus politics, & STAT’s Health Tech Summit

Episode 127: Eric Topol on Stephen Hahn, plus Covid-19 vaccine timelines, & the 2000th First Opinion

Episode 126: The FDA's chaotic week, Trump's effect on science, and Musk's big reveal

Episode 125: Shocking FDA rejections, a longevity science setback & Derek Lowe on Covid-19 vaccines

Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies